Johannes Fruehauf

Johannes Fruehauf has extensive experience in the life sciences industry. In 2009, they founded BioLabs, a shared laboratory coworking space for startup companies. In 2011, they co-founded Mission BioCapital, a seed-stage investment firm with AUM for Healthcare and Life Sciences companies. In 2012, they founded LabCentral, the center for life science startups in Kendall Square, Cambridge. In 2016, they became a Board Member of Vaxess Technologies, a company developing innovative solutions for stabilization and delivery of vaccines. In 2018, they became a Founding Investor and Board Director of Tidal Therapeutics, a company developing in-vivo reprogramming for T-Cells, and a Founding Investor and Observer of Totient, a company using machine learning and advanced biology to develop therapeutic antibodies. Johannes also became a Board Member of QurAlis and Sentien Biotechnologies, Inc., and a Board Member of Pandion Therapeutics in 2018. In 2019, they became a Board Member of Arkuda Therapeutics. In 2021, Tidal Therapeutics was acquired by Sanofi and Totient was acquired by Absci. In February 2021, Pandion announced its $1.86bn acquisition by Merck.

Johannes Fruehauf completed a Postdoc at Harvard Medical School in Molecular Biology from 2002 to 2004. Johannes then went on to receive a MD from Goethe University from 1989 to 1997. In 1994 and 1995, they studied Medicine at the University of Montpellier. Lastly, they completed a Fellowship at SLP Boston 2012 in Entrepreneurship/Entrepreneurial Studies from 2011 to 2012.